EP
EBS icon

Edgestream Partners’s Emergent Biosolutions EBS Stock Holding History

Edgestream Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-68,826
Closed -$713K – 759
2023
Q1 		$713K Sell
68,826
-25,727
-27% -$311K 0.08% 348
2022
Q4 		$1.12M Buy
94,553
+72,292
+325% +$1.12M 0.13% 242
2022
Q3 		$467K Buy
+22,261
New +$619K 0.04% 349

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Edgestream Partners's EBS Position: Q2 2023 in Review

Edgestream Partners sold out of Emergent Biosolutions (EBS) in Q2 2023, closing a stake of 68,826 shares — an estimated $713K sold.

Edgestream Partners first reported a position in EBS in Q3 2022 and held it in 3 quarters. The position peaked at $1.12M in Q4 2022. 183 funds tracked by Wall St. Rank hold EBS as of Q2 2023.

  • Edgestream Partners reported no remaining Emergent Biosolutions position as of Q2 2023 after selling out during the quarter.
  • Edgestream Partners sold 68,826 Emergent Biosolutions shares in Q2 2023, an estimated $713K.
  • Edgestream Partners first reported a position in Emergent Biosolutions in Q3 2022 and held it in 3 quarters.
  • Edgestream Partners's Emergent Biosolutions position peaked at $1.12M in Q4 2022.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2023.

Based on Edgestream Partners's 13F filing for Q2 2023, filed 10 Aug 2023.